BACKGROUND: The effect of anti-platelet drugs on surgical blood loss and perioperative complications has not been studied in depth and the management of surgical patients taking anti-platelet medications is controversial. OBJECTIVE: To assess the effect of anti-platelet therapy on perioperative blood loss in patients undergoing appendectomy either laparoscopically or via open surgery. METHODS: We reviewed the files of all patients 40 years old who underwent open or laparoscopic appendectomies from 2007 to 2010. Excluded were patients with short hospitalization and no follow-up of hemoglobin level, patients on warfarin treatment and patients who underwent additional procedures. Estimation of blood loss was based on decrease in hemoglobin level from admission to discharge. Risk factors for blood loss, such as anti-platelet therapy, age, gender, surgical approach, surgical time, surgical findings and complications, were analyzed. RESULTS: The final cohort included 179 patients (mean age 61 +/- 14 years, range 40-93) of whom 65 were males. The mean perioperative hemoglobin decrease was 1.59 +/- 1.07 mg/dl (range 0-5 mg/dl). Thirty-nine patients received anti-platelet therapy prior to surgery and 140 did not. No significant differences in decrease of hemoglobin level were found between patients receiving anti-platelet therapy and those who were not (1.73 +/- 1.21 vs. 1.55 +/- 1.02 mg/dl, P = 0.3). In addition, no difference was found between patients on anti-platelettherapy operated laparoscopically and those operated in an open fashion (1.59 +/- 1.18 vs. 2.04 +/- 1.28 mg/ dl, P = 0.29). Five patients required blood transfusions, two of whom were on anti-platelet therapy. Blood loss was significantly greater in patients with a perforated appendicitis and in those with an operative time of more than one hour. CONCLUSIONS: Anti-platelet therapy does not pose a risk for increased blood loss following emergent appendectomy performed either laparoscopically or in an open fashion.
BACKGROUND: The effect of anti-platelet drugs on surgical blood loss and perioperative complications has not been studied in depth and the management of surgical patients taking anti-platelet medications is controversial. OBJECTIVE: To assess the effect of anti-platelet therapy on perioperative blood loss in patients undergoing appendectomy either laparoscopically or via open surgery. METHODS: We reviewed the files of all patients 40 years old who underwent open or laparoscopic appendectomies from 2007 to 2010. Excluded were patients with short hospitalization and no follow-up of hemoglobin level, patients on warfarin treatment and patients who underwent additional procedures. Estimation of blood loss was based on decrease in hemoglobin level from admission to discharge. Risk factors for blood loss, such as anti-platelet therapy, age, gender, surgical approach, surgical time, surgical findings and complications, were analyzed. RESULTS: The final cohort included 179 patients (mean age 61 +/- 14 years, range 40-93) of whom 65 were males. The mean perioperative hemoglobin decrease was 1.59 +/- 1.07 mg/dl (range 0-5 mg/dl). Thirty-nine patients received anti-platelet therapy prior to surgery and 140 did not. No significant differences in decrease of hemoglobin level were found between patients receiving anti-platelet therapy and those who were not (1.73 +/- 1.21 vs. 1.55 +/- 1.02 mg/dl, P = 0.3). In addition, no difference was found between patients on anti-platelettherapy operated laparoscopically and those operated in an open fashion (1.59 +/- 1.18 vs. 2.04 +/- 1.28 mg/ dl, P = 0.29). Five patients required blood transfusions, two of whom were on anti-platelet therapy. Blood loss was significantly greater in patients with a perforated appendicitis and in those with an operative time of more than one hour. CONCLUSIONS: Anti-platelet therapy does not pose a risk for increased blood loss following emergent appendectomy performed either laparoscopically or in an open fashion.